Clinical and genetic profile of patients with primary hyperoxaluria: observation from a single centre from West India
DOI:
https://doi.org/10.18203/2349-3291.ijcp20210475Keywords:
Primary hyperoxaluria, End stage kidney disease, Genetic testingAbstract
Background: Primary hyperoxaluria (PH) is characterized by oxalate overproduction due to glyoxylate pathway enzyme defects in the liver. Apart from heterogeneous clinical manifestations of PH, diagnosis by urinary and plasma oxalate levels or stone analysis is not always confirmatory. Mutational analysis is required for definite diagnosis. There is heterogeneity between genotype of PH patients between Western and Indian population. The aim of this study is to describe clinical and genetic profile of Indian patients, diagnosed with PH in Western India.
Methods: All clinical PH suspects in Nephrology and Paediatric Nephrology units from October 2016-September 2020, were counselled for genetic analysis for diagnostic confirmation. Cases, genetically confirmed to have PH, were included and retrospectively analysed for their clinical profile, modality of renal replacement therapy, survival/death. The mutations identified in our patients were compared with commonly prevalent mutations in world PH databases.
Results: 13 of 15 patients were identified to have genetically confirmed PH. Median age at diagnosis was 1 year (range, 4 months to 46 years) and six (46.15%) were male. Six (46.15%) infants, two (15.38%) adolescents and five (38.46%) presented in adulthood. Nine presented as ESKD, while three patients progressed to ESKD during study. Eight (61.54%) with AGXT mutation were diagnosed as PH type1, four (30.76%) GRHPR mutation while one (7.69%) female infant had PH type 3 with HOGA mutation. Out of thirteen, five (38.46%) patients expired, five (38.46%) are ESKD requiring dialysis. Two (15.38%) post-transplant patients, graft loss for one and another requiring supportive medical management for deteriorating eGFR.
Conclusions: ESKD being commonest presentation, high index of suspicion in all cases with renal stone and complete work up should be done for early diagnosis and timely intervention. National registry is required for detection of novel PH mutations in Indian population.
References
Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:649-58.
Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. Kidney Int. 2011;80:1278-291.
Cregeen DP, Williams EL, Hulton S, Rumsby G. Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Human mutation. 2003;22(6):497.
Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. The American Journal of Human Genetics. 2010;87(3):392-9.
Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clinical Journal of the American Society of Nephrology. 2012;7(3):458-65.
North American Paediatric Renal Trials and Collaborative Studies (NAPRTCS) Annual Report.
Hattori S, Yosioka K, Honda M, Ito H. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. Pediatric Nephrol. 2002;17(6):456-61.
Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. International journal of nephrology. 2011;2011.
Hoppe B. An update on primary hyperoxaluria. Nature Rev Nephrol. 2012;8(8):467.
Chanchlani R, Sinha A, Gulati A, Agarwal V, Bagga A. Common mutation underlying primary hyperoxaluria type1 in three Indian children. Indian journal of nephrology. 2012;22(6):459.
Sethi SK, Waterham HR, Sharma S, Sharma A, Hari P, Bagga A. Primary Hyperoxaluria type 1 with a novel mutation. Indian J Pediatr 2009;216-7.
Pinapala A, Garg M, Kamath N, Iyengar A. Clinical and Genetic Profile of Indian Children with Primary hyperoxaluria. Indian J Nephrol 2017;27(3):222-224.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics Med. 2015;17(5):405-23.
US National Library of Medicine, Genetics Home Reference. https://www.nlm.nih.gov/genetics. Last accessed on
Soliman NA, Nabhan MM, Abdelrahman SM, Abdelaziz H, Helmy R, Ghanim K et al. Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center. Nephrologie Therapeutique. 2017;13(3):176-82.
Van der Hoeven SM, Van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dialysis Transpl. 2012;27(10):3855-62.
Kemper MJ, Conrad S, Müller-Wiefel DE. Primary hyperoxaluria type 2. Euro J Pediatr. 1997;156(7):509-12.
Johnson SA, Rumsby G, Cregeen D, Hulton SA. Primary hyperoxaluria type 2 in children. Pediatric Nephrol. 2002;17(8):597-601.
Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 2019;96(6):1389-99.
Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. The Am J Human Genetics. 2010;87(3):392-9.
Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Society Nephrol. 2011;6(9):2289-95.
Williams EL, Bockenhauer D, Van’t Hoff WG, Johri N, Laing C, Sinha MD et al. The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrology Dialysis Transplantation. 2012;27(8):3191-5.
Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ et al. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. European J Human Genetics. 2013;21(2):162-72.
Van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney international. 2004;66(2):746-52.
Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005;67(5):1704-9.
Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: strategy for organ transplantation. Current Opinion in Organ Transplantation. 2010;15(5):590-3.
